Risk for Impaired Cardiovascular Function: A Comprehensive Nursing Diagnosis Care Map

Introduction

Heart failure (HF) is a pervasive and intricate clinical syndrome arising from diverse functional or structural cardiac disorders. It fundamentally impairs the heart’s ability to effectively fill with or eject blood, thereby failing to meet the metabolic demands of the body’s tissues and organs. This condition manifests from a spectrum of underlying diseases, with the majority of patients exhibiting symptoms stemming from compromised left ventricular myocardial function. Common clinical presentations include dyspnea, fatigue, diminished exercise tolerance, and fluid retention, clinically evident as pulmonary and peripheral edema. Recognizing the risk for impaired cardiovascular function is paramount in nursing care, necessitating a robust nursing diagnosis care map to guide effective interventions and improve patient outcomes.

Heart failure is further classified based on left ventricular ejection fraction (LVEF). Heart failure with reduced ejection fraction (HFrEF) is defined as LVEF of 40% or less, while heart failure with preserved ejection fraction (HFpEF) is characterized by LVEF greater than 40%. Both classifications underscore the critical need for vigilant monitoring and targeted nursing interventions to mitigate the risk for impaired cardiovascular function and associated complications.

Nursing Diagnoses Related to Cardiovascular Function

In the context of heart failure and risk for impaired cardiovascular function, several key nursing diagnoses are pertinent. These diagnoses guide the development of a comprehensive nursing diagnosis care map, ensuring holistic patient care. Primary nursing diagnoses include:

• Decreased Cardiac Output
• Activity Intolerance
• Excess Fluid Volume
• Risk for Impaired Skin Integrity
• Ineffective Peripheral Tissue Perfusion
• Ineffective Breathing Pattern
• Impaired Gas Exchange
• Fatigue
• Anxiety
• Risk for Impaired Cardiovascular Function (Primary Focus)

This article will particularly focus on the risk for impaired cardiovascular function nursing diagnosis, providing a framework for assessment, intervention, and evaluation within a comprehensive care map.

Etiology of Heart Failure and Cardiovascular Impairment

Heart failure is not a disease itself but rather a clinical syndrome resulting from various underlying pathologies. These include conditions affecting the pericardium, myocardium, endocardium, cardiac valves, vasculature, or metabolic processes. Systolic dysfunction (HFrEF), the inability of the heart to contract forcefully enough to eject sufficient blood, is commonly attributed to idiopathic dilated cardiomyopathy (DCM), coronary heart disease (ischemic heart disease), hypertension, and valvular heart disease. Diastolic dysfunction (HFpEF), characterized by the heart’s inability to relax and fill adequately, shares similar etiological factors, with the addition of hypertrophic obstructive cardiomyopathy and restrictive cardiomyopathy. Understanding these causes is crucial in identifying patients at risk for impaired cardiovascular function.

Risk Factors Contributing to Impaired Cardiovascular Function

Numerous risk factors elevate an individual’s susceptibility to heart failure and subsequent impaired cardiovascular function. These factors are critical components in assessing the risk for impaired cardiovascular function and developing preventative or management strategies within a nursing care plan. Key risk factors include:

• Coronary Artery Disease (CAD): Reduced blood flow to the heart muscle weakens it over time.
• Myocardial Infarction (MI): Damage to the heart muscle from a heart attack directly impairs function.
• Hypertension: Chronic high blood pressure increases the workload on the heart, leading to hypertrophy and eventual failure.
• Diabetes Mellitus: Damages blood vessels and the heart muscle, increasing the risk of heart failure.
• Obesity: Places extra strain on the heart and is often associated with other risk factors like hypertension and diabetes.
• Smoking: Damages blood vessels and increases the risk of CAD and hypertension.
• Alcohol Use Disorder: Excessive alcohol consumption can directly damage the heart muscle (alcoholic cardiomyopathy).
• Atrial Fibrillation: Irregular heart rhythm can lead to inefficient heart function and increased risk of heart failure.
• Thyroid Diseases: Both hyperthyroidism and hypothyroidism can stress the cardiovascular system.
• Congenital Heart Disease: Structural abnormalities present from birth can predispose to heart failure.
• Aortic Stenosis: Narrowing of the aortic valve increases the heart’s workload.

Assessment of Patients at Risk for Impaired Cardiovascular Function

A thorough assessment is essential to identify patients at risk for impaired cardiovascular function and to monitor the progression of heart failure. Assessment should encompass both subjective symptoms reported by the patient and objective clinical signs.

Symptoms of heart failure can be broadly categorized into those resulting from fluid overload and those from reduced cardiac output. Fluid overload symptoms include dyspnea (shortness of breath), orthopnea (difficulty breathing when lying flat), edema (swelling, particularly in the lower extremities), pain from hepatic congestion (right upper quadrant discomfort), and abdominal distension from ascites (fluid accumulation in the abdomen). Reduced cardiac output manifests as fatigue and weakness, especially pronounced during physical exertion.

The presentation of heart failure can vary in acuity. Acute and subacute presentations (developing over days to weeks) are marked by:

• Shortness of breath at rest or with exertion
• Orthopnea
• Paroxysmal nocturnal dyspnea (sudden nighttime breathlessness)
• Right upper quadrant discomfort due to acute hepatic congestion

Palpitations, sometimes accompanied by lightheadedness, may indicate atrial or ventricular tachyarrhythmias, further compromising cardiovascular function.

Chronic presentations (developing over months) may emphasize:

• Fatigue
• Anorexia (loss of appetite)
• Abdominal distension
• Peripheral edema

Anorexia in chronic heart failure is multifactorial, stemming from poor perfusion of the splanchnic circulation, bowel edema, and nausea induced by hepatic congestion.

Characteristic physical findings in patients with heart failure include:

• Pulsus alternans: Alternating strong and weak peripheral pulses, indicative of ventricular dysfunction.
• Displaced Apical Impulse: Palpable point of maximal impulse shifted laterally past the midclavicular line, suggesting left ventricular enlargement.
• S3 Gallop: A low-frequency heart sound in early diastole, a sensitive indicator of ventricular dysfunction.
• Peripheral Edema: Swelling in the extremities due to fluid retention.
• Pulmonary Rales (Crackles): Abnormal lung sounds indicating fluid in the alveoli.

The New York Heart Association (NYHA) Functional Classification provides a standardized method to categorize the severity of heart failure based on symptoms and activity level:

• Class I: Symptoms occur only with activity exceeding ordinary daily exertion.
• Class II: Symptoms develop with ordinary daily activities.
• Class III: Symptoms arise with minimal activity.
• Class IV: Symptoms are present even at rest.

This classification is invaluable in assessing the impact of impaired cardiovascular function on the patient’s daily life and in guiding the nursing diagnosis care map.

Figure: Chest Radiograph Revealing Pulmonary Congestion in Congestive Heart Failure. This image illustrates the characteristic pulmonary edema seen in heart failure, a key indicator of impaired cardiovascular function.

Diagnostic Evaluation of Impaired Cardiovascular Function

Several diagnostic tests are employed to evaluate patients suspected of heart failure and to assess the extent of impaired cardiovascular function. These tests are essential for confirming the nursing diagnosis and tailoring the care plan.

• Electrocardiogram (ECG): Detects evidence of myocardial infarction (acute or prior), ischemia, and rhythm abnormalities like atrial fibrillation, all contributing to risk for impaired cardiovascular function.
• Chest X-ray: Identifies cardiomegaly (cardiac-to-thoracic ratio > 50%), cephalization of pulmonary vessels, Kerley B-lines (indicating interstitial edema), and pleural effusions, signs of heart failure and impaired cardiovascular function.
• Blood Tests:
  • Cardiac Troponin (T or I): Elevated levels indicate myocardial damage.
  • Complete Blood Count (CBC): Assesses overall health and can identify anemia, which can exacerbate heart failure.
  • Serum Electrolytes: Evaluates electrolyte imbalances, which can affect cardiac function.
  • Blood Urea Nitrogen (BUN) and Creatinine: Assess renal function, often compromised in heart failure.
  • Liver Function Tests (LFTs): Detect hepatic congestion.
  • Brain Natriuretic Peptide (BNP) or NT-proBNP: Elevated levels are strong indicators of heart failure and impaired cardiovascular function, providing greater diagnostic value than other initial tests.
• Transthoracic Echocardiogram (TTE): Crucial for assessing ventricular function (ejection fraction), valve function, and hemodynamics, directly evaluating the degree of impaired cardiovascular function.

Medical Management Strategies to Improve Cardiovascular Function

Medical management of heart failure aims to alleviate symptoms, improve quality of life, reduce hospitalizations, and prolong survival. Pharmacological and device therapies are cornerstones of this management, directly addressing the impaired cardiovascular function.

Pharmacological agents commonly used include:

• Diuretics: Reduce fluid overload, alleviating symptoms like dyspnea and edema.
• Beta-blockers: Decrease heart rate and blood pressure, reducing cardiac workload and improving long-term outcomes in HFrEF.
• Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs): Reduce vasoconstriction and fluid retention, improving survival in HFrEF.
• Angiotensin Receptor Neprilysin Inhibitor (ARNI): Sacubitril/valsartan, an ARNI, has shown superior outcomes compared to ACEIs in HFrEF by enhancing natriuretic peptides and blocking the renin-angiotensin-aldosterone system.
• Hydralazine and Nitrate: Combination therapy effective in African-Americans with persistent NYHA class III to IV HF and HFrEF despite optimal medical therapy.
• Digoxin: Improves contractility and controls heart rate, used primarily for symptom management.
• Aldosterone Antagonists: Spironolactone and eplerenone reduce fluid retention and improve survival in selected patients with HFrEF.

Device therapies play a critical role in managing severe heart failure and reducing the risk for impaired cardiovascular function complications:

• Implantable Cardioverter-Defibrillator (ICD): Prevents sudden cardiac death in patients at high risk of ventricular arrhythmias.
• Cardiac Resynchronization Therapy (CRT): Biventricular pacing improves coordination of heart contractions, enhancing cardiac output and symptoms in patients with conduction delays and reduced LVEF. Often combined with ICD (CRT-D).
• Ventricular Assist Devices (VADs): Mechanical pumps that support heart function, used as a bridge to transplant or as destination therapy for patients with advanced heart failure.
• Cardiac Transplant: A definitive treatment for end-stage heart failure when other therapies fail.

Nursing Management and Care Map for Risk for Impaired Cardiovascular Function

Nursing care is integral to the management of patients with heart failure and those at risk for impaired cardiovascular function. A comprehensive nursing diagnosis care map guides nursing interventions, focusing on symptom management, patient education, and preventing complications. The care map for risk for impaired cardiovascular function should address the following key areas:

Nursing Diagnosis: Risk for Impaired Cardiovascular Function related to [specify risk factors, e.g., myocardial damage, hypertension, valvular disease].

Desired Outcomes:

• Patient will maintain adequate cardiac output as evidenced by [specify indicators, e.g., stable vital signs, absence of edema, adequate urine output, absence of dyspnea at rest].
• Patient will demonstrate understanding of heart failure management strategies.
• Patient will adhere to prescribed medication regimen and lifestyle modifications.
• Patient will report symptoms of worsening heart failure promptly.

Nursing Interventions (Care Map Components):

1. Comprehensive Cardiovascular Assessment:

   • Regularly monitor vital signs (heart rate, blood pressure, respiratory rate, oxygen saturation).
   • Assess heart sounds for S3, S4 gallops, murmurs.
   • Auscultate lung sounds for rales or wheezing.
   • Evaluate peripheral pulses, capillary refill, and skin color and temperature.
   • Monitor for edema (location, severity).
   • Assess for signs and symptoms of decreased cardiac output (fatigue, weakness, dizziness, chest pain).
   • Utilize NYHA classification to track functional status.

2. Optimize Fluid Balance:

   • Monitor daily weight and fluid intake/output.
   • Administer diuretics as prescribed and monitor for effectiveness and side effects (electrolyte imbalances, dehydration).
   • Restrict sodium intake (2-3 g/day) and fluid intake (2 L/day) as ordered and educate patient on rationale and implementation.
   • Elevate legs when sitting to promote venous return and reduce edema.

3. Promote Adequate Tissue Perfusion:

   • Monitor for signs of poor peripheral perfusion (cool extremities, delayed capillary refill, pallor, cyanosis).
   • Encourage regular, moderate physical activity as tolerated to improve circulation.
   • Administer medications as prescribed to improve cardiac output and reduce afterload (ACEIs, ARBs, ARNIs, beta-blockers).

4. Enhance Respiratory Function and Gas Exchange:

   • Position patient in high Fowler’s position to facilitate breathing.
   • Administer supplemental oxygen as needed to maintain adequate oxygen saturation.
   • Monitor respiratory rate, depth, and effort.
   • Teach patient breathing exercises and techniques to manage dyspnea.

5. Manage Fatigue and Activity Intolerance:

   • Encourage rest periods and pacing of activities.
   • Assist with activities of daily living as needed to conserve energy.
   • Monitor patient’s response to activity and adjust activity levels accordingly.
   • Address factors contributing to fatigue, such as anemia or sleep disturbances.

6. Reduce Anxiety:

   • Provide a calm and supportive environment.
   • Encourage patient to express concerns and fears.
   • Provide clear and concise information about heart failure and its management.
   • Teach relaxation techniques and stress management strategies.

7. Promote Medication Adherence:

   • Provide thorough education about medications (purpose, dosage, side effects, administration).
   • Simplify medication regimens if possible.
   • Assess and address barriers to medication adherence (cost, complexity, side effects).
   • Utilize medication aids (pillboxes, reminders) as needed.

8. Patient Education and Health Promotion:

   • Teach patients about heart failure pathophysiology, risk factors, and management.
   • Emphasize the importance of medication compliance, low-sodium diet, fluid restriction, and daily weight monitoring.
   • Educate on recognizing and reporting worsening symptoms (weight gain, increased edema, increased dyspnea, fatigue, chest pain).
   • Counsel on lifestyle modifications: smoking cessation, limiting alcohol intake, weight management, regular exercise within limitations.
   • Provide resources and support groups for heart failure patients and their families.

Evaluation:

• Regularly evaluate the effectiveness of nursing interventions based on desired patient outcomes.
• Monitor patient’s progress towards improved cardiac output, symptom control, and adherence to the care plan.
• Adjust the care plan as needed based on patient response and ongoing assessment findings.
• Evaluate patient’s understanding of heart failure management and self-care strategies.

When to Seek Prompt Medical Attention

Patients should be educated on recognizing and promptly reporting worsening symptoms that indicate escalating risk for impaired cardiovascular function. Immediate medical assessment is warranted in the following situations:

• Worsening fluid overload symptoms (rapid weight gain, increased edema, worsening dyspnea).
• Worsening hypoxia (increased shortness of breath, cyanosis).
• Uncontrolled tachycardia (rapid heart rate) regardless of rhythm.
• Change in cardiac rhythm (palpitations, irregular pulse).
• Change in mental status (confusion, dizziness, lightheadedness).
• Decreased urinary output despite diuretic therapy.

Continuous Monitoring for Optimal Cardiovascular Function

Ongoing monitoring is crucial for patients with heart failure to detect changes in condition and adjust management strategies promptly. This includes:

• Frequent monitoring of vital signs, including oxygen saturation.
• Telemetry monitoring for continuous heart rate and rhythm assessment, especially in acute settings or for patients with arrhythmias.
• Regular assessment for heart failure symptoms and overall clinical status.
• Daily weight monitoring at home to detect early fluid retention.

Interprofessional Coordination of Care

Effective management of heart failure and risk for impaired cardiovascular function requires a collaborative interprofessional team. This team typically includes:

• Primary Care Physician
• Emergency Department Physician
• Cardiologist
• Radiologist
• Cardiac Nurses
• Internist
• Cardiac Surgeons
• Pharmacist
• Dietitian
• Social Worker

Coordination of care is essential to address the multifaceted needs of patients with heart failure. Nurses play a pivotal role in this coordination, ensuring effective communication among team members, advocating for patient needs, and providing comprehensive patient education.

Health Education and Promotion for Long-Term Cardiovascular Health

Patient education is paramount for improving clinical outcomes, reducing hospital readmissions, and empowering patients to manage their condition effectively. Key areas for health teaching and health promotion include:

• Self-monitoring of symptoms at home and prompt reporting of changes.
• Strict medication adherence and understanding of medication regimens.
• Daily weight monitoring and understanding of weight trends.
• Dietary sodium restriction (2-3 g/day) and fluid restriction (2 L/day).
• Lifestyle modifications: smoking cessation, moderate alcohol intake, weight management, regular exercise within limitations.
• Management of comorbidities such as diabetes, hypertension, and sleep apnea.
• Importance of follow-up appointments and ongoing medical care.

Nurse-driven education at discharge and throughout the continuum of care has been proven to significantly improve therapy compliance and enhance patient outcomes in heart failure management, directly mitigating the risk for impaired cardiovascular function.

Discharge Planning for Continuity of Care

Effective discharge planning is crucial for ensuring a smooth transition from hospital to home and for maintaining continuity of care. Discharge planning should encompass:

• Comprehensive patient education on all aspects of heart failure management.
• Detailed medication reconciliation and clear instructions for medication management.
• Reinforcement of dietary and fluid restrictions.
• Activity and exercise recommendations tailored to the patient’s functional status.
• Smoking cessation and alcohol moderation counseling.
• Strategies for recognizing and managing worsening heart failure symptoms.
• Scheduled follow-up appointments with cardiology and primary care providers.
• Referral to home healthcare services or cardiac rehabilitation programs as needed.

Nurse-led discharge education is a critical component of discharge planning, contributing significantly to improved patient compliance and better outcomes in heart failure management, ultimately reducing the long-term risk for impaired cardiovascular function.

Conclusion

Managing the risk for impaired cardiovascular function in patients with heart failure requires a multifaceted approach grounded in comprehensive nursing care. The nursing diagnosis care map provides a structured framework for assessment, intervention, and evaluation, guiding nurses in delivering patient-centered care. By focusing on key nursing diagnoses, implementing evidence-based interventions, and prioritizing patient education, nurses play a vital role in improving outcomes, enhancing quality of life, and mitigating the long-term impact of heart failure on cardiovascular function. Continuous monitoring, interprofessional collaboration, and robust discharge planning are essential to ensure ongoing support and optimize cardiovascular health for these vulnerable patients.

References

1.Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW., ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 03;145(18):e895-e1032. [PubMed: 35363499]

2.Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016 Jun;13(6):368-78. [PMC free article: PMC4868779] [PubMed: 26935038]

3.CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987 Jun 04;316(23):1429-35. [PubMed: 2883575]

4.Lind L, Ingelsson M, Sundstrom J, Ärnlöv J. Impact of risk factors for major cardiovascular diseases: a comparison of life-time observational and Mendelian randomisation findings. Open Heart. 2021 Sep;8(2) [PMC free article: PMC8438838] [PubMed: 34518286]

5.Noubiap JJ, Agbor VN, Bigna JJ, Kaze AD, Nyaga UF, Mayosi BM. Prevalence and progression of rheumatic heart disease: a global systematic review and meta-analysis of population-based echocardiographic studies. Sci Rep. 2019 Nov 19;9(1):17022. [PMC free article: PMC6863880] [PubMed: 31745178]

6.Kim KH, Pereira NL. Genetics of Cardiomyopathy: Clinical and Mechanistic Implications for Heart Failure. Korean Circ J. 2021 Oct;51(10):797-836. [PMC free article: PMC8484993] [PubMed: 34327881]

7.Rezkalla SH, Kloner RA. Viral myocarditis: 1917-2020: From the Influenza A to the COVID-19 pandemics. Trends Cardiovasc Med. 2021 Apr;31(3):163-169. [PMC free article: PMC7965406] [PubMed: 33383171]

8.Muchtar E, Blauwet LA, Gertz MA. Restrictive Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circ Res. 2017 Sep 15;121(7):819-837. [PubMed: 28912185]

9.Shams P, Ahmed I. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 30, 2023. Cardiac Amyloidosis. [PubMed: 35593829]

10.Brown KN, Pendela VS, Ahmed I, Diaz RR. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 30, 2023. Restrictive Cardiomyopathy. [PubMed: 30725919]

11.Matta AG, Carrié D. Epidemiology, Pathophysiology, Diagnosis, and Principles of Management of Takotsubo Cardiomyopathy: A Review. Med Sci Monit. 2023 Mar 06;29:e939020. [PMC free article: PMC9999670] [PubMed: 36872594]

12.Bairashevskaia AV, Belogubova SY, Kondratiuk MR, Rudnova DS, Sologova SS, Tereshkina OI, Avakyan EI. Update of Takotsubo cardiomyopathy: Present experience and outlook for the future. Int J Cardiol Heart Vasc. 2022 Apr;39:100990. [PMC free article: PMC8913320] [PubMed: 35281752]

13.Ahmad SA, Brito D, Khalid N, Ibrahim MA. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 22, 2023. Takotsubo Cardiomyopathy. [PubMed: 28613549]

14.DeFilippis EM, Beale A, Martyn T, Agarwal A, Elkayam U, Lam CSP, Hsich E. Heart Failure Subtypes and Cardiomyopathies in Women. Circ Res. 2022 Feb 18;130(4):436-454. [PMC free article: PMC10361647] [PubMed: 35175847]

15.Wong CM, Hawkins NM, Jhund PS, MacDonald MR, Solomon SD, Granger CB, Yusuf S, Pfeffer MA, Swedberg K, Petrie MC, McMurray JJ. Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). J Am Coll Cardiol. 2013 Nov 12;62(20):1845-54. [PubMed: 23850914]

16.Sciomer S, Moscucci F, Salvioni E, Marchese G, Bussotti M, Corrà U, Piepoli MF. Role of gender, age and BMI in prognosis of heart failure. Eur J Prev Cardiol. 2020 Dec;27(2_suppl):46-51. [PMC free article: PMC7691623] [PubMed: 33238736]

17.Volpe M, Gallo G. Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC). Front Cardiovasc Med. 2023;10:1136340. [PMC free article: PMC10040794] [PubMed: 36993998]

18.Kim DY, Kim SH, Ryu KH. Tachycardia induced Cardiomyopathy. Korean Circ J. 2019 Sep;49(9):808-817. [PMC free article: PMC6713829] [PubMed: 31456374]

19.Anakwue RC, Onwubere BJ, Anisiuba BC, Ikeh VO, Mbah A, Ike SO. Congestive heart failure in subjects with thyrotoxicosis in a black community. Vasc Health Risk Manag. 2010 Aug 09;6:473-7. [PMC free article: PMC2922308] [PubMed: 20730063]

20.Schoenenberger AW, Schoenenberger-Berzins R, der Maur CA, Suter PM, Vergopoulos A, Erne P. Thiamine supplementation in symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled, cross-over pilot study. Clin Res Cardiol. 2012 Mar;101(3):159-64. [PubMed: 22057652]

21.DiNicolantonio JJ, Liu J, O’Keefe JH. Thiamine and Cardiovascular Disease: A Literature Review. Prog Cardiovasc Dis. 2018 May-Jun;61(1):27-32. [PubMed: 29360523]

22.Reddy YNV, Melenovsky V, Redfield MM, Nishimura RA, Borlaug BA. High-Output Heart Failure: A 15-Year Experience. J Am Coll Cardiol. 2016 Aug 02;68(5):473-482. [PubMed: 27470455]

23.Chayanupatkul M, Liangpunsakul S. Cirrhotic cardiomyopathy: review of pathophysiology and treatment. Hepatol Int. 2014 Jul;8(3):308-15. [PMC free article: PMC4160726] [PubMed: 25221635]

24.Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW., American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020 Mar 03;141(9):e139-e596. [PubMed: 31992061]

25.Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993 Oct;22(4 Suppl A):6A-13A. [PubMed: 8376698]

26.Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P., American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017 Mar 07;135(10):e146-e603. [PMC free article: PMC5408160] [PubMed: 28122885]

27.Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, Brauer M, Kutty VR, Gupta R, Wielgosz A, AlHabib KF, Dans A, Lopez-Jaramillo P, Avezum A, Lanas F, Oguz A, Kruger IM, Diaz R, Yusoff K, Mony P, Chifamba J, Yeates K, Kelishadi R, Yusufali A, Khatib R, Rahman O, Zatonska K, Iqbal R, Wei L, Bo H, Rosengren A, Kaur M, Mohan V, Lear SA, Teo KK, Leong D, O’Donnell M, McKee M, Dagenais G. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2020 Mar 07;395(10226):795-808. [PMC free article: PMC8006904] [PubMed: 31492503]

28.Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet. 2006 Jan 28;367(9507):356-67. [PubMed: 16443044]

29.Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol. 2012 Sep-Oct;21(5):365-71. [PubMed: 22227365]

30.Ait Mou Y, Bollensdorff C, Cazorla O, Magdi Y, de Tombe PP. Exploring cardiac biophysical properties. Glob Cardiol Sci Pract. 2015;2015:10. [PMC free article: PMC4448074] [PubMed: 26779498]

31.Abassi Z, Khoury EE, Karram T, Aronson D. Edema formation in congestive heart failure and the underlying mechanisms. Front Cardiovasc Med. 2022;9:933215. [PMC free article: PMC9553007] [PubMed: 36237903]

32.Prausmüller S, Arfsten H, Spinka G, Freitag C, Bartko PE, Goliasch G, Strunk G, Pavo N, Hülsmann M. Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF. J Am Heart Assoc. 2020 Jun 02;9(11):e015071. [PMC free article: PMC7428996] [PubMed: 32427034]

33.Docherty KF, Vaduganathan M, Solomon SD, McMurray JJV. Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. JACC Heart Fail. 2020 Oct;8(10):800-810. [PMC free article: PMC8837825] [PubMed: 33004114]

34.Obokata M, Reddy YNV, Borlaug BA. Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods. JACC Cardiovasc Imaging. 2020 Jan;13(1 Pt 2):245-257. [PMC free article: PMC6899218] [PubMed: 31202759]

35.Kao DP, Lewsey JD, Anand IS, Massie BM, Zile MR, Carson PE, McKelvie RS, Komajda M, McMurray JJ, Lindenfeld J. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail. 2015 Sep;17(9):925-35. [PMC free article: PMC4654630] [PubMed: 26250359]

36.Harjola VP, Mullens W, Banaszewski M, Bauersachs J, Brunner-La Rocca HP, Chioncel O, Collins SP, Doehner W, Filippatos GS, Flammer AJ, Fuhrmann V, Lainscak M, Lassus J, Legrand M, Masip J, Mueller C, Papp Z, Parissis J, Platz E, Rudiger A, Ruschitzka F, Schäfer A, Seferovic PM, Skouri H, Yilmaz MB, Mebazaa A. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2017 Jul;19(7):821-836. [PMC free article: PMC5734941] [PubMed: 28560717]

37.King M, Kingery J, Casey B. Diagnosis and evaluation of heart failure. Am Fam Physician. 2012 Jun 15;85(12):1161-8. [PubMed: 22962896]

38.Ali AS, Rybicki BA, Alam M, Wulbrecht N, Richer-Cornish K, Khaja F, Sabbah HN, Goldstein S. Clinical predictors of heart failure in patients with first acute myocardial infarction. Am Heart J. 1999 Dec;138(6 Pt 1):1133-9. [PubMed: 10577445]

39.Klein L, O’Connor CM, Leimberger JD, Gattis-Stough W, Piña IL, Felker GM, Adams KF, Califf RM, Gheorghiade M., OPTIME-CHF Investigators. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation. 2005 May 17;111(19):2454-60. [PubMed: 15867182]

40.Kelder JC, Cramer MJ, van Wijngaarden J, van Tooren R, Mosterd A, Moons KG, Lammers JW, Cowie MR, Grobbee DE, Hoes AW. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation. 2011 Dec 20;124(25):2865-73. [PubMed: 22104551]

41.Rørth R, Jhund PS, Yilmaz MB, Kristensen SL, Welsh P, Desai AS, Køber L, Prescott MF, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJV. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circ Heart Fail. 2020 Feb;13(2):e006541. [PubMed: 32065760]

42.Hacker M, Hoyer X, Kupzyk S, La Fougere C, Kois J, Stempfle HU, Tiling R, Hahn K, Störk S. Clinical validation of the gated blood pool SPECT QBS processing software in congestive heart failure patients: correlation with MUGA, first-pass RNV and 2D-echocardiography. Int J Cardiovasc Imaging. 2006 Jun-Aug;22(3-4):407-16. [PubMed: 16328851]

43.Jain S, Londono FJ, Segers P, Gillebert TC, De Buyzere M, Chirinos JA. MRI Assessment of Diastolic and Systolic Intraventricular Pressure Gradients in Heart Failure. Curr Heart Fail Rep. 2016 Feb;13(1):37-46. [PubMed: 26780916]

44.Cahill TJ, Ashrafian H, Watkins H. Genetic cardiomyopathies causing heart failure. Circ Res. 2013 Aug 30;113(6):660-75. [PubMed: 23989711]

45.Peterson PN, Rumsfeld JS, Liang L, Albert NM, Hernandez AF, Peterson ED, Fonarow GC, Masoudi FA., American Heart Association Get With the Guidelines-Heart Failure Program. A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association get with the guidelines program. Circ Cardiovasc Qual Outcomes. 2010 Jan;3(1):25-32. [PubMed: 20123668]

46.Lam CSP, Mulder H, Lopatin Y, Vazquez-Tanus JB, Siu D, Ezekowitz J, Pieske B, O’Connor CM, Roessig L, Patel MJ, Anstrom KJ, Hernandez AF, Armstrong PW., VICTORIA Study Group. Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. J Am Heart Assoc. 2021 Nov 16;10(22):e021094. [PMC free article: PMC8751950] [PubMed: 34743540]

47.Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O’Connor CM., VICTORIA Study Group. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020 May 14;382(20):1883-1893. [PubMed: 32222134]

48.Lucas C, Johnson W, Hamilton MA, Fonarow GC, Woo MA, Flavell CM, Creaser JA, Stevenson LW. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000 Dec;140(6):840-7. [PubMed: 11099986]

49.Rider I, Sorensen M, Brady WJ, Gottlieb M, Benson S, Koyfman A, Long B. Disposition of acute decompensated heart failure from the emergency department: An evidence-based review. Am J Emerg Med. 2021 Dec;50:459-465. [PubMed: 34500232]